MétaCan
Menu
Back to cohort
Record W2006347666 · doi:10.1097/yic.0b013e3282f424d6

Weight gain during olanzapine treatment for psychotic depression: effects of dose and age

2008· article· en· W2006347666 on OpenAlexafffund
Eric G. Smith, Anthony J. Rothschild, Moonseong Heo, Catherine Peasley‐Miklus, Melynda Caswell, Eros Papademetriou, Alastair J. Flint, Benoit H. Mulsant, Barnett S. Meyers

Bibliographic record

VenueInternational Clinical Psychopharmacology · 2008
Typearticle
Languageen
FieldMedicine
TopicSchizophrenia research and treatment
Canadian institutionsUniversity of TorontoToronto Rehabilitation InstituteToronto General HospitalUniversity Health Network
FundersNational Center for Advancing Translational SciencesNational Institute of Mental HealthPfizer CanadaForest LaboratoriesPfizerEli Lilly and CompanyAmerican Psychiatric Institute for Research and EducationU.S. Public Health ServiceAstraZeneca
KeywordsOlanzapineWeight gainMedicineBody mass indexDepression (economics)ConfoundingConfidence intervalPlaceboSertralineInternal medicineSchizophrenia (object-oriented programming)PsychologyPsychiatryBody weightAntidepressant

Abstract

fetched live from OpenAlex

Weight gain has often been associated with olanzapine treatment, yet little is known about the influence of patient age or cumulative dose on olanzapine-associated weight gain. The first 118 participants in the National Institutes of Mental Health Study of the Pharmacotherapy of Psychotic Depression randomized clinical trial (ClinicalTrials.gov Registration NCT00056472) completing at least 4 weeks of treatment with olanzapine were analyzed to determine the relationship between weight gain, age, and cumulative olanzapine dose. Younger (age 18-59 years) and older (age 60+ years) participants received open-label olanzapine and either sertraline or placebo for up to 12 weeks. Linear mixed effect regression modeling was used to determine the effects of age and cumulative olanzapine dose on weight gain, controlling for potential confounders. Age was observed to have a significant negative association with weight gain (P=0.01), even after controlling for differences in cumulative dose and baseline body mass index. Each 10-year increase in age was associated with a decrease in mean weight gain over 12 weeks of approximately 0.6 kg (95% confidence interval: 0.14-1.05 kg). Cumulative olanzapine dose was also significantly associated with weight gain (P<0.0001). Approximately 60% of completers of the 12-week trial experienced clinically significant weight gain (> or =7% of baseline weight).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.371
Threshold uncertainty score0.456

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.065
GPT teacher head0.461
Teacher spread0.395 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations17
Published2008
Admission routes2
Has abstractyes

Explore more

Same venueInternational Clinical PsychopharmacologySame topicSchizophrenia research and treatmentFrench-language works237,207